These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21357627)

  • 1. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007.
    George PM; Banya W; Pareek N; Bilton D; Cullinan P; Hodson ME; Simmonds NJ
    BMJ; 2011 Feb; 342():d1008. PubMed ID: 21357627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.
    Aitken ML; Burke W; McDonald G; Shak S; Montgomery AB; Smith A
    JAMA; 1992 Apr; 267(14):1947-51. PubMed ID: 1548827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis.
    Konstan MW; VanDevanter DR; Sawicki GS; Pasta DJ; Foreman AJ; Neiman EA; Morgan WJ
    Ann Am Thorac Soc; 2018 Apr; 15(4):485-493. PubMed ID: 29313709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group.
    Cobos N; Danés I; Gartner S; González M; Liñán S; Arnau JM
    Eur J Pediatr; 2000 Mar; 159(3):176-81. PubMed ID: 10664231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.
    Konstan MW; Wagener JS; Pasta DJ; Millar SJ; Jacobs JR; Yegin A; Morgan WJ;
    Pediatr Pulmonol; 2011 Jun; 46(6):545-53. PubMed ID: 21438174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV
    Ramos KJ; Quon BS; Heltshe SL; Mayer-Hamblett N; Lease ED; Aitken ML; Weiss NS; Goss CH
    Chest; 2017 Jun; 151(6):1320-1328. PubMed ID: 28115168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pregnancy on survival in women with cystic fibrosis.
    Goss CH; Rubenfeld GD; Otto K; Aitken ML
    Chest; 2003 Oct; 124(4):1460-8. PubMed ID: 14555580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wasting as an independent predictor of mortality in patients with cystic fibrosis.
    Sharma R; Florea VG; Bolger AP; Doehner W; Florea ND; Coats AJ; Hodson ME; Anker SD; Henein MY
    Thorax; 2001 Oct; 56(10):746-50. PubMed ID: 11562511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
    Ryan G; Mukhopadhyay S; Singh M
    Cochrane Database Syst Rev; 2000; (2):CD001021. PubMed ID: 10796732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients.
    Augarten A; Akons H; Aviram M; Bentur L; Blau H; Picard E; Rivlin J; Miller MS; Katznelson D; Szeinberg A; Shmilovich H; Paret G; Laufer J; Yahav Y
    Pediatr Transplant; 2001 Oct; 5(5):339-42. PubMed ID: 11560752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis.
    Milla CE
    Thorax; 1998 Dec; 53(12):1014-7. PubMed ID: 10195070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the effects of long-term dornase alfa use on lung function using registry data.
    Newsome SJ; Daniel RM; Carr SB; Bilton D; Keogh RH
    J Cyst Fibros; 2019 Jan; 18(1):110-117. PubMed ID: 30172681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
    Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
    Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase.
    Johnson JA; Connolly MA; Jacobs P; Montgomery M; Brown NE; Zuberbuhler P
    Pharmacotherapy; 1999 Oct; 19(10):1159-66. PubMed ID: 10512065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Musculoskeletal techniques for clinically stable adults with cystic fibrosis: a preliminary randomised controlled trial.
    Sandsund CA; Roughton M; Hodson ME; Pryor JA
    Physiotherapy; 2011 Sep; 97(3):209-17. PubMed ID: 21820539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.
    Schluchter MD; Konstan MW; Davis PB
    Stat Med; 2002 May; 21(9):1271-87. PubMed ID: 12111878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.
    Zach MS
    Thorax; 1996 Jul; 51(7):750-5. PubMed ID: 8882085
    [No Abstract]   [Full Text] [Related]  

  • 19. Lung function decline from adolescence to young adulthood in cystic fibrosis.
    Vandenbranden SL; McMullen A; Schechter MS; Pasta DJ; Michaelis RL; Konstan MW; Wagener JS; Morgan WJ; McColley SA;
    Pediatr Pulmonol; 2012 Feb; 47(2):135-43. PubMed ID: 22241571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil.
    Silva GF; J Simmonds N; Roth Dalcin PT
    BMC Pulm Med; 2020 Jul; 20(1):194. PubMed ID: 32677921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.